Nature Reviews Drug Discovery contents October 2016 Volume 15 Number 10 pp 661-729

If you are unable to see the message below, click here to view.

Advertisement
New Ebook on Choosing Biomarker Discovery Tools  Need help choosing the right biomarker discovery tool for your research needs. This new eBook provides a high-level comparison of two of the most promising proteomic technologies - mass spectrometry and the newer SOMAmer® reagent-based SOMAscan® assay - for hypothesis-free protein biomarker discovery.
TABLE OF CONTENTS
October 2016 Volume 15 Number 10		Advertisement
2015 2-year Impact Factor 47.120 Journal Metrics 2-year Median 31	In this issue Comment News and Analysis Research Highlights Reviews Also this month  Featured article: Biophysics in drug discovery: impact, challenges and opportunities Jean-Paul Renaud, Chun-wa Chung, U. Helena Danielson, Ursula Egner, Michael Hennig, Roderick E. Hubbard & Herbert Nar	nature.com webcasts Springer Nature presents a custom webcast on: Automating Continuous Cell Culture Date:Tuesday October 11, 2016 Time: 7AM PDT, 10AM EDT, 3PM BST, 4PM CEST Speaker: Oliver Gaßmann, Application Specialist, Beckman Coulter Life Sciences Register for the webcast and live Q&A session Sponsored by:  Beckman Coulter Life Sciences
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Working at Roche in Switzerland We're looking for committed scientists who share our passion to make a difference for millions of patients. Learn more
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
A new open access journal dedicated to publishing the most important scientific advances in all aspects of genomics and its application in the practice of medicine. Part of the Nature Partner Journals series, the journal is published in partnership with the Center of Excellence in Genomic Medicine Research.  Open for submissions
Advertisement
nature.com webcasts Springer Nature presents a custom webcast on: Optimizing sensitivity and specificity in the RT-QuIC assay using BMG plate readers Date: Wednesday October 19, 2016 Time: 8AM PDT, 11AM EDT, 4PM BST, 5PM CEST  Register for FREE at   And learn how the RT-QuIC assay is currently being used as a diagnostic in the clinical setting for CJD and has the potential to be a valuable screening tool. Sponsored by: BMG LABTECH
Comment: Open data in drug discovery and development: lessons from malaria Timothy N. C. Wells, Paul Willis, Jeremy N. Burrows & Rob Hooft van Huijsduijnen p661 | doi:10.1038/nrd.2016.154 There is a growing consensus that drug discovery thrives in an open environment. Here, we describe how the malaria community has embraced four levels of open data — open science, open innovation, open access and open source — to catalyse the development of new medicines, and consider principles that could enable open data approaches to be applied to other disease areas. Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
The cancer vaccine resurgence Asher Mullard p663 | doi:10.1038/nrd.2016.201 A wave of companies are developing personalized vaccines, built from tumour-specific neo-antigens, providing a timely boost for a failure-ridden area of cancer immunotherapy. PDF
FDA eyes new diabetes end points Katie Kingwell p666 | doi:10.1038/nrd.2016.202 A recent FDA workshop brought new diabetes outcome measures to the table, focusing on patient-oriented end points. PDF
NEWS IN BRIEF Merck & Co. drops osteoporosis drug odanacatib Asher Mullard p669 | doi:10.1038/nrd.2016.207 PDF
NEWS IN BRIEF Cardiovascular pipeline decline quantified Asher Mullard p669 | doi:10.1038/nrd.2016.208 PDF
NEWS IN BRIEF New vaccine coalition targets epidemics Asher Mullard p669 | doi:10.1038/nrd.2016.209 PDF
BIOBUSINESS BRIEFS Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA Sean Khozin, Meredith Chuk, Tamy Kim, Suranjan De, Sanjay Sahoo, Geoffrey Kim & Richard Pazdur p670 | doi:10.1038/nrd.2016.189 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q4 2016 Tara Hansen p671 | doi:10.1038/nrd.2016.186 PDF
AN AUDIENCE WITH Michael Rosenblatt p672 | doi:10.1038/nrd.2016.203 Michael Rosenblatt, newly appointed Chief Medical Officer of Flagship Ventures and former Chief Medical Officer at Merck & Co., discusses his move from industry to venture capital. PDF
FROM THE ANALYST'S COUCH Investigating investment in biopharmaceutical R&D Percy H. Carter, Ernst R. Berndt, Joseph A. DiMasi & Mark Trusheim p673 | doi:10.1038/nrd.2016.104 Recent investments in nascent public biopharmaceutical companies indicate that companies focused on small-molecule approaches attracted more funding than might have been expected based on rates of return on investment compared with biologic approaches. PDF
RESEARCH HIGHLIGHTS Top Viral infection: New tricks to treat Ebola p675 | doi:10.1038/nrd.2016.191 PDF Antiparasitic drugs: Proteasome inhibition combats kinetoplastid infections p676 | doi:10.1038/nrd.2016.190 PDF Cancer: Tumour-specific ablation of Treg cells induces anticancer response p676 | doi:10.1038/nrd.2016.198 PDF Analgesia: Screening for cleaner pain relief p677 | doi:10.1038/nrd.2016.204 PDF Inflammatory diseases: Anti-CD1a antibody reduces inflammation in psoriasis p678 | doi:10.1038/nrd.2016.192 PDF IN BRIEF Regenerative medicine: Inhibiting Hippo repairs tissue | Stroke: Promoting neuronal recovery | Muscle disorders: Preventing diaphragm dysfunction | Cancer: BMI1 inhibition reverses lung cancer PDF Nature Reviews Drug Discovery JOBS of the week Postdoctoral Research Fellow in Medicinal Chemistry for Cancer Drug Discovery University of Michigan More Science jobs from Nature Reviews Drug Discovery EVENT Equivalence of Complex Drug Products: Scientific and Regulatory Challenges 09.11.16 New York, USA More science events from
Advertisement
nature.com webcasts Springer Nature presents a custom webcast on: uDISCO for whole organs and organisms: A new way of large sample imaging Date: Thursday October 27, 2016 Time: 8AM PDT, 11AM EDT, 4PM BST, 5PM CEST Register for FREE Sponsored by: Bitplane LaVision Biotech Andor Technology
REVIEWS		Top
Biophysics in drug discovery: impact, challenges and opportunities Jean-Paul Renaud, Chun-wa Chung, U. Helena Danielson, Ursula Egner, Michael Hennig, Roderick E. Hubbard & Herbert Nar p679 | doi:10.1038/nrd.2016.123 Over the past 25 years, biophysical technologies such as X-ray crystallography and nuclear magnetic resonance spectroscopy have become key components of drug discovery platforms in many pharmaceutical companies and academic laboratories. This article provides a framework to understand this evolution by describing the key biophysical methods, the information they can provide and the ways they can be applied at different stages of the drug discovery process. Abstract | Full Text | PDF
Drug discovery in advanced prostate cancer: translating biology into therapy Timothy A. Yap, Alan D. Smith, Roberta Ferraldeschi, Bissan Al-Lazikani, Paul Workman & Johann S. de Bono p699 | doi:10.1038/nrd.2016.120 The progression of prostate cancer to castration-resistant prostate cancer (CRPC) poses considerable therapeutic challenges. Johann de Bono and colleagues review the identification of possible drug targets in CRPC, the evolving CRPC therapeutic landscape and what the future of the treatment of the disease may hold. Abstract | Full Text | PDF | Supplementary information
The ever-expanding myokinome: discovery challenges and therapeutic implications Martin Whitham & Mark A. Febbraio p719 | doi:10.1038/nrd.2016.153 Myokines are emerging as potential mediators of some of the beneficial effects of exercise on the body. Here, Whitham and Febbraio discuss the challenges facing the discovery and validation of myokines and highlight selected myokines with the potential to be therapeutically exploited in cancer and metabolic disease. Abstract | Full Text | PDF
Advertisement
nature.com webcasts Join us for our upcoming webcast with live Q&A:  PAIN TARGETING MECHANISMS Presented by BioPharma Dealmakers Date: Thursday, October 6, 2016 Time: 8AM PDT, 11AM EDT, 4PM BST, 5PM CEST REGISTER FOR FREE Sponsored by: Algomedix, Inc. | Cara Therapeutics, Inc. | Myoscience | Nektar Therapeutics
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.